How were Teligent's earnings last quarter?

Teligent, Inc. (NASDAQ:TLGT) posted its earnings results on Monday, August, 16th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.01. The business had revenue of $10.43 million for the quarter.

When did Teligent's stock split?

Shares of Teligent reverse split on Thursday, May 28th 2020. The 1-10 reverse split was announced on Wednesday, May 27th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 27th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Tim Sawyer's approval rating as Teligent's CEO?

2 employees have rated Teligent Chief Executive Officer Tim Sawyer on Glassdoor.com . Tim Sawyer has an approval rating of 100% among the company's employees. This puts Tim Sawyer in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Teligent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teligent investors own include Novavax (NVAX) , ChemoCentryx (CCXI) , Voyager Therapeutics (VYGR) , AbbVie (ABBV) , General Electric (GE) , Biocept (BIOC) , Lannett (LCI) , Pfizer (PFE) , Selecta Biosciences (SELB) and VBI Vaccines (VBIV) .

NASDAQ:TLGT

Teligent (TLGT) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free TLGT Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.01
▼
$0.05
52-Week Range: N/A

Volume: 6,460 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Teligent alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Teligent Stock (NASDAQ:TLGT)

Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

Find out more here >>>

TLGT Stock News Headlines

April 23, 2023 | wsj.com

IDT Corp. Cl B

July 18, 2022 | finance.yahoo.com

Lidocaine Market Size is projected to reach USD 3.05 Billion by 2029, growing at a CAGR of 8.45%: Straits Research - Yahoo Finance

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

June 21, 2022 | law360.com

Revlon Case Opens, And LATAM Lands Its Ch. 11 Plan - Law360

June 17, 2022 | law360.com

Teligent's Post-Sale Drug Recall Puts Its Ch. 11 Plan In Doubt - Law360

May 3, 2022 | finance.yahoo.com

Topical Drugs Market Size to Grow by USD 70.95 billion from 2021 to 2026 | Driven by Increase in the Prevalence of Skin Diseases | Technavio - Yahoo Finance

April 27, 2022 | law360.com

Teligent Gets Ch. 11 Disclosure, Voting Plans OK'd In Del. - Law360

April 26, 2022 | law360.com

US Trustee Calls Teligent Ch. 11 Plan Releases 'Baffling' - Law360

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 12, 2022 | law360.com

Teligent OK'd For Fast-Tracked Del. Ch. 11 Disclosure Hearing - Law360

April 1, 2022 | wsj.com

Alex Mandl, Who Gave Up a Top AT&T Job to Lead a Startup, Has Died at Age 78 - The Wall Street Journal

February 28, 2022 | bizjournals.com

Teligent seeks to convert bankruptcy to Chapter 7 amid impasse with creditors - Philadelphia Business Journal - Philadelphia Business Journal

February 25, 2022 | law360.com

Teligent Says Stalled Plan Talks Make Liquidation Best Option - Law360

February 9, 2022 | news.yahoo.com

Robber to be resentenced because judge forgot to ask a question - Yahoo News

February 8, 2022 | law360.com

Teligent Lender Slams Creditor Group Bid To Claw Back Cash - Law360

February 3, 2022 | prnewswire.com

PAI further bolsters its portfolio with the acquisition of Teligent Sterile Injectable and Topical products - PRNewswire

February 3, 2022 | morningstar.co.uk

Hikma completes acquisition of Teligent's Canadian... - Morningstar

January 19, 2022 | law360.com

Teligent's 3 Ch. 11 Asset Sales Bring $87M Into Estate - Law360

January 18, 2022 | law360.com

Teligent's Three Ch. 11 Asset Sales Bring $87M Into Estate - Law360

January 17, 2022 | marketwatch.com

Hikma to Buy Canadian Assets of Teligent for $45.75 Mln - MarketWatch

January 17, 2022 | lse.co.uk

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million | Financial News - London South East

January 17, 2022 | prnewswire.com

Hikma expands into Canada with acquisition of Teligent sterile injectable assets - PRNewswire

December 14, 2021 | law360.com

3-Part Ch.11 Stalking Horse Sale OK'd For Teligent - Law360

December 8, 2021 | nasdaq.com

FDA Approves Daré Bioscience's Xaciato For Bacterial Vaginosis - Nasdaq

December 8, 2021 | finance.yahoo.com

Rocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer - Yahoo Finance

December 2, 2021 | marketwatch.com

Atropine Sulfate Market Analysis By Industry Size, Share, Revenue Growth, Development And Demand Forecast To 2028

November 11, 2021 | wsj.com

Plaintiffs Want Teligent Price-Fixing Lawsuit to Continue Despite Bankruptcy - The Wall Street Journal

See More Headlines

Receive TLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teligent and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/16/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TLGT
CUSIP: N/A
CIK: 352998
Web: www.teligent.com
Phone: (856) 697-1441
Fax: 856-697-1442
Employees: 2,357
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Timothy B. Sawyer
President, Chief Executive Officer & Director
Antonio di Nicola
Vice President-Operations & General Manager
Alyssa Lozynski
Chief Financial Officer
Devendra Shah
Vice President-Research & Development
Philip K. Yachmetz
Secretary, Chief Legal Officer & Executive VP

Key Competitors

View All Competitors

TLGT Stock Analysis - Frequently Asked Questions

How were Teligent's earnings last quarter?: Teligent, Inc. (NASDAQ:TLGT) posted its earnings results on Monday, August, 16th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.01. The business had revenue of $10.43 million for the quarter.
When did Teligent's stock split?: Shares of Teligent reverse split on Thursday, May 28th 2020. The 1-10 reverse split was announced on Wednesday, May 27th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 27th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What is Tim Sawyer's approval rating as Teligent's CEO?: 2 employees have rated Teligent Chief Executive Officer Tim Sawyer on Glassdoor.com. Tim Sawyer has an approval rating of 100% among the company's employees. This puts Tim Sawyer in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Teligent own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Teligent investors own include Novavax (NVAX), ChemoCentryx (CCXI), Voyager Therapeutics (VYGR), AbbVie (ABBV), General Electric (GE), Biocept (BIOC), Lannett (LCI), Pfizer (PFE), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

This page (NASDAQ:TLGT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Teligent (TLGT) Stock Price, News & Analysis

About Teligent Stock (NASDAQ:TLGT)

TLGT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

TLGT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info